| Abstract [eng] |
There are many organisations trying to improve Diabetes Mellitus diagnostics, enhance glycaemia management of diabetes patients, because insufficient and late diagnosis increases formation, and complications progress. The purpose of this work was evolution of influence, of different methodological approaches to of glycated hemoglobin results. Samples of 100 patients with Diabetes Mellitus was analyzed for glucose and HbA1c. There was shown correlation between average concentration glucose‘s during three months coefficient. HbA1c was analyzed using three analytical systems of Roche-Hitachi 917, Bayer-Advia1650 and Dade Behring-Dimension RxL standardized according different standardization recommendations: International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), Diabetes Control and Complications Trial (DCCT), National Glycohemoglobin Standardization Program (NGSP). Roche-Hitachi 917 results standardized according IFCC recommendations were chosen as reference. Correlation and differences between analytical systems were as follows. Roche-Hitachi 917 (IFCC) – Bayer-Advia1650 (NGSP): r = 1.017 [0.883 to 1.188]; y = 3.068 [1.894 to 4.142]; n = 52; p = 0.0000001. Roche-Hitachi 917 (DCCT) – Bayer-Advia1650 (NGSP): r = 1.132 [1.060 to 1.209]; y = 0.282 [-0.476 to 0.990]; n = 53; p = 0.001. Roche-Hitachi 917 (IFCC) – Dade Behring-Dimension RxL (DCCT): 0.886 [0.767 to 1.021]; y = 2.422 [1.630 to 3.413]; n = 52; p = 0.0000001. Roche-Hitachi 917 (DCCT) – Dade Behring-Dimension RxL (DCCT): r = 0.987 [0.920 to 1.059]; y = -0.086 [-0.730 to 0.446]; n = 53; p = 0.001. Meanwhile results of two analytical systems (Roche-Hitachi 917, Dade Behring-Dimension RxL) standardized according same recommendation Diabetes Control and Complications Trial (DCCT) were on goad agreement. |
